Colitis has been reported with some anti-CD20 therapies in multiple sclerosis (MS), but not previously with ofatumumab.
Objectives:
To report the first case of ofatumumab-associated colitis in MS and discuss its implications.
Methods:
Case report.
Results:
A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) developed severe colitis 3 months after initiating ofatumumab, requiring hospitalization and treatment discontinuation.
Conclusion:
This case suggests a potential class effect of anti-CD20 therapies, including ofatumumab, in relation to colitis in MS. Clinicians should monitor for gastrointestinal symptoms in MS patients receiving any anti-CD20 therapy.
HauserSLBar-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383(6): 546–557.
2.
PalanichamyAJahnSNicklesD, et al. Rituximab efficiently depletes increased CD20 expressing T cells in multiple sclerosis patients. J Immunol2014; 193(2): 580–586.
3.
KimTBrinkerACroteauD, et al. Immune-mediated colitis associated with ocrelizumab: A new safety risk. Mult Scler2023; 29(10): 1275–1281.
4.
LeeHHSritharanNBerminghamD, et al. Ocrelizumab-induced severe colitis. Case Rep Gastrointest Med2020; 2020: 8858378.
5.
Quesada-SimóAGarrido-MarínANosP, et al. Impact of anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: A review. Front Pharmacol2023; 14: 1186016.
6.
GoetzMAtreyaRGhalibafianM, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis2007; 13(11): 1365–1368.
7.
TolaymatSSharmaKKagziY, et al. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord2023; 75: 104763.
8.
FeuersteinJDHoEYShmidtE, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology2021; 160(7): 2496–2508.
9.
HauserSLCreeBA. Treatment of multiple sclerosis: A review. Am J Med2020; 133(12): 1380–1390.e2.
10.
SandbornWJFeaganBGD’HaensG, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med2021; 385: 1280–1291.
